3rd International Conference on CRISPR Technologies

From basic biology to versatile technologies: The CRISPR-Cas immune system and its applications in basic research, biotechnology, medicine, and agriculture
September 16-18, 2019

Presented by the Society for Biological Engineering (SBE), the CRISPR Tech 2019 conference will bring together academics and industry representatives to highlight the cutting edge of these developments and the most immediate technical and societal challenges.

Poster Presentations should fit within a 40"x40" space.

Submit an Abstract Register Today

CRISPR Tech 2019 Flyer

Technical Program

    NSF’s support may be available to students/post docs who submit an abstract. Women and members of underrepresented groups are strongly encouraged to apply.

Transportation Information

CRISPR technologies represent versatile tools that have impacted sectors spanning from basic research and biotechnology to human health and agriculture. These technologies continue to develop at an astounding pace, with new advances and applications being reported on a seemingly daily basis. The CRISPR Tech 2019 conference will bring together academics and industry representatives to highlight the cutting edge of these developments and the most immediate technical and societal challenges. The conference will also discuss the basic features of CRISPR-Cas systems as defense mechanisms found in bacteria and archaea, and how new insights into these systems can give rise to the next generation of technologies. The conference venue will be in Würzburg, Germany, a picturesque German town centrally located in Europe and easily reached by train from Frankfurt and Munich international airports.

    Keynote Speakers

    Invited Speakers

    Conference Chairs

    Session Topics

    • CRISPR-Cas biology
    • Foundational technologies
    • Medical applications
    • Policy and ethics
    • Agricultural applications
    • Bacterial applications

    Organizing Committee

    Featured Speakers

    David Bikard

    David is a young investigator at the Institut Pasteur in the department of Microbiology where he started his group in 2014. David obtained an engineer degree from AgroParisTech as well as a master degree and PhD from Paris Diderot University for his work performed at the Institut Pasteur on the integron bacterial recombination system. He then joined the laboratory of Luciano Marraffini at the Rockefeller University as a postdoctoral fellow where he started to work on CRISPR-Cas systems. He pioneered the use of CRISPR-Cas systems to edit bacterial genomes, control gene expression and kill...Read more

    Laurakay Bruhn

    Laurakay Bruhn is Section Manager of Biological Chemistry in Agilent Research Labs and manages programs and projects aimed at developing technology breakthroughs in nucleic acid synthesis, gene editing and control, proteomics and metabolomics as well as other efforts related to developing new technologies for the life sciences research to diagnostics continuum. The group she leads has leveraged a novel RNA oligo synthesis chemistry developed at Agilent to invent new ways to use chemical modifications in guide RNAs to enhance the activity and specificity of CRISPR systems.

    After...Read more

    Andrea Crisanti

    Andrea Crisanti is professor of molecular parasitology at Imperial College, graduated in Medicine at the University of Rome "la Sapienza' and carried his doctoral work at the Basel Institute for Immunology. Prof. Crisanti has also been appointed full professor of Microbiology and Clinical Microbiology at the University of Perugia where until recently has coordinated the Centre of Functional Genomics. He has pioneered the molecular biology of the human malaria vector Anopheles gambiae and has made a number of important scientific contributions that advanced the genetic and molecular knowledge of the malaria parasite and its mosquito vector.Read more

    Paul Donohoue

    Paul is a Scientist at Caribou Biosciences in the Technology Development group. He received his B.S. from the University of California, Davis in Biochemistry and Molecular Biology. As an early employee at Caribou, his initial research centered on identifying the key structural features of the Type II guide RNAs that drive Cas9 functionality and orthogonality. In the Technology Development group, he has focused on the development of genome-wide assays to quantify off-target cleavage events as well as the engineering of advanced technologies to increase Cas protein specificity. ...Read more

    Karmella A. Haynes

    Karmella Haynes is an Associate Professor of Biomedical Engineering at Emory University. She earned her Ph.D. studying epigenetics and chromatin in Drosophila at Washington University, St. Louis. Postdoctoral fellowships at Davidson College and Harvard Medical School introduced her to synthetic biology. Today, her research aims to identify how the intrinsic properties of chromatin, the DNA-protein structure that packages eukaryotic genes, can be used to control cell development in tissues. Her HHMI postdoctoral fellowship project on bacterial computers was recognized as “Publication...Read more

    Kevin Holden

    Kevin Holden is Head of Synthetic Biology at Synthego in Redwood City, California where he is responsible for integrating synthetic biology workflows, such as CRISPR genome engineering, into novel engineering and automation platforms. He has over 10 years of biotechnology experience that includes synthetic biology, engineering metabolic pathways in microbes and collaborative research. Kevin earned his PhD in Microbiology from University of California, Davis. He is originally from the UK and immigrated to the US in his youth.Read more

    Ashley Jacobi

    Ashley Jacobi is a Senior Staff Scientist in the Molecular Genetics Research and Development group at IDT.  Ashley has been with IDT for 12 years and during that time she has published 18 manuscripts in peer-reviewed journals, contributed to numerous patent applications, and has presented at a wide variety of international biomedical research conferences.  She has been conducting research in RNAi and antisense oligo technologies, and more recently has been focusing on the development of novel CRISPR RNA sequences and modification patterns that allow for more efficient and...Read more

    Yinan Kan

    Yinan Kan is the Principle Scientist in the eGenesis gene editing team. He received his Ph.D. degree in 2015 in Biochemistry, Molecular Biology and Biophysics in the University of Minnesota with a research focus of dissecting the DNA repair pathways underlying homology-directed genome editing. He conducted postdoc research at Harvard Medical School before joining eGenesis Inc. He is devoted to developing novel technological platforms for multiplexed, precision and long-range genome editing with the aim of delivering safe and effective human transplantable organs from...Read more

    Lina Leon

    Lina M. Leon is a 4th year Ph.D. candidate in Dr. Joseph Bondy-Denomy’s group at UCSF and a recipient of the HHMI Gilliam Fellowship for Advanced Study. Prior to her graduate work, she completed a B.S. in chemistry at the University of Florida and was awarded an HHMI undergraduate research fellowship that she completed at UCSF.

    Lina’s work primarily focuses on the biological underpinnings of Cas3-based CRISPR immunity and phage-encoded anti-CRISPR activity. She is eager to apply these lessons learned from bacteria and phage to develop and improve on genome engineering using Cas3....Read more

    Ioannis Mougiakos

    Ioannis earned his PhD (cum laude/with honors) in 2019 from Wageningen University (the Netherlands) in genetic and metabolic engineering of thermophilic and mesophilic bacteria. During his PhD project he focused on the characterization of a thermotolerant Cas9 orthologue (ThermoCas9) and the development of the first Cas9-based genome engineering tool for thermophilic bacteria. Moreover, he worked on the adaptation of CRISPR-Cas and antiCRISPR systems as genetic engineering tools for non-model mesophilic and thermophilic bacteria. He further employed these tools for engineering the...Read more

    Florian Schmidt

    2011 - 2017 Undergrad (Heidelberg, Germany): B.Sc. + M.Sc. in Molecular Biotechnology.

    2014 - 2016 Dirk Grimm Lab (Heidelberg, Germany): AAV gene therapy and CRISPR genome engineering.

    2016: Feng Zhang Lab,  Broad Institute (Boston, USA): In vivo CRISPR screens using lentivirus and AAV-vectors.

    2017 - now: Randall Platt Lab (Basel, Switzerland): PhD student in the Laboratory for Biological Engineering at ETH Zuerich....Read more

    Tom Schreiber

    During my PhD in the lab of Ulla Bonas (2010-2015, MLU Halle) I worked in the field of plant pathogen interactions, with particular interest in type 3 effector proteins of the transcription activator-like effector (TALE) family. TALEs allowed, for the first time, the design of artificial DNA-binding proteins with high specificity and a broad spectrum of applications including genome editing. After my PhD I moved to the field of synthetic biology in the lab of Alain Tissier (2015-now, IPB Halle). Here I expanded the repertoire of programmable tools for nucleic acid targeting (amiRNAs,...Read more

    Gerald Schwank

    Gerald Schwank started his group as an Assistant Professor of Stem Cell Biology & Disease Modeling in October 2014. He studied Genetics and Microbiology at the University of Vienna, and obtained his PhD in 2009 from the University of Zurich under the supervision of Prof. Konrad Basler. During his PhD he studied growth control in the Drosophila wing disc epithelium, and found that complementary gradients of growth factors drive uniform cell proliferation. After an additional two years at the University of Zurich as a postdoctoral fellow, he moved in 2011 to the Netherlands to the lab of...Read more

    Ekaterina Semenova

    Ekaterina graduated from the Department of Natural Sciences, Novosibirsk State University. As a pre-doctoral fellow, she studied the genetic diversity of microbes from Lake Baikal and received her PhD in Genetics at the Institute of Cytology and Genetics at the Russian Academy of Sciences. Ekaterina joined the laboratory of Konstantin Severinov at the Waksman Institute for Microbiology at Rutgers University in 2003. She has been studying different aspects of bacterophage-host interactions, regulation of phage development, and bacterial defense mechanisms such as restriction-modification...Read more

    Virginijus Siksnys

    Virginijus Siksnys studied chemistry at Vilnius University and obtained his Ph.D from Moscow State University before returning to Vilnius where he moved through different research ranks at the Institute of Applied Enzymology/Institute of Biotechnology. Since 2002 he holds the position of Professor of Vilnius University and serves as Chief scientist at the Institute of Biotechnology. Dr. Siksnys has made a major and sustained contribution to the understanding of the structure and function of restriction enzymes. His research on the CRISPR-Cas has had a major impact on the field. His studies...Read more

    Thorsten Stafforst

    Thorsten Stafforst started his independent lab in 2011 at the University of Tübingen, where he is now full professor for nucleic acid biochemistry. He studied Chemistry at the University of Göttingen, obtained his PhD in 2005 in Bioorganic Chemistry, and moved for a Postdoc with Prof. Don Hilvert at ETH Zurich. His research is focussed on the engineering of programmable RNA-targeted proteins. His lab has a particularly strong focus on therapeutic RNA editing by either engineering editases (gene therapy) or by designing antisense oligonucleotides that are tailored to harness endogenous...Read more

    Mike Terns

    CRISPR-Cas systems are recently discovered RNA-based adaptive immune systems that control invasions of viruses and other mobile genetic elements in prokaryotes (bacteria and archaea).

    CRISPR-Cas systems function by capturing short invader sequences within the CRISPR locus of the host genome, producing short crRNAs from the CRISPR locus transcripts, and using the crRNAs to guide Cas protein-containing immune effector complexes to recognize and destroy the invading nucleic acids.

    CRISPR-Cas based immunity is mediated by numerous and diverse Cas proteins and a given organism may...Read more